Vispa-Cel, an Allogeneic Anti-CD19 CAR-T cell Therapy with a PD-1 Knockout, In Patients with relapsed/refractory B cell Non-Hodgkin Lymphoma (r/r B-NHL): Updated Results from the Antler Phase 1 Clinical Trial

Transplantation and Cellular Therapy 2026

View at publisher
Authors: Mehdi Hamadani, Houston Holmes, James Essell, Ayad Hamdan, Boyu Hu, Elizabeth Brém, Rushang D. Patel, Sunita Nasta, Costas K. Yannakou, Mohamad Cherry, Don A. Stevens, Umar Farooq
+36 more Kenneth Micklethwaite, Vamsi Kota, Abraham S. Kanate, Tatyana Feldman, Melhem M Solh, David Lavie, B. Carnley, Muhammad Husnain, Cesar Gentille Sanchez, Fevzi Yalniz, Gary Simmons, Donna Marcy, Erin Mullane, Jim Peck, Ine-Mari Bornman, Chris Holland, Shally Chung, Ashraf Garrett, Govind Shah, Lindsay McFarland, Mara Bryan, Karen Lyle, Paul D. Donohoue, Elizabeth Garner, Pingping Mao, Eric Stawiski, Tom Kochy, Justin Skoble, Elaine Alambra, Enrique Zudaire, Tonia Nesheiwat, Tina Albertson, Maria do Socorro Oliveira Portella, Stephen J. Schuster, Loretta J. Nastoupil, Susan O'Brien
DOI: 10.1016/j.jtct.2026.02.013
Cited by: 2

Fields of Study & Subjects

CAR-T cell therapy research Cutaneous lymphoproliferative disorders research Biosimilars and Bioanalytical Methods

Publication details

Journal / source
Transplantation and Cellular Therapy
Publisher
Elsevier BV
Volume
32
Issue
3
Pages
S1–S1
Publication date
1 March 2026
Language
EN